Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBITDA Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBITDA Margin for 4 consecutive years, with 272.6% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 8455.0% to 272.6% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 48.05% through Dec 2025, down 2950.0% year-over-year, with the annual reading at 48.05% for FY2025, 2950.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 272.6% at bioAffinity Technologies, up from 155.47% in the prior quarter.
  • The five-year high for EBITDA Margin was 272.6% in Q4 2025, with the low at 166806.19% in Q1 2023.
  • Average EBITDA Margin over 4 years is 25529.09%, with a median of 155.47% recorded in 2025.
  • The sharpest move saw EBITDA Margin skyrocketed 16672697bps in 2024, then crashed -10926bps in 2025.
  • Over 4 years, EBITDA Margin stood at 68902.77% in 2022, then skyrocketed by 100bps to 98.32% in 2023, then soared by 291bps to 188.05% in 2024, then soared by 45bps to 272.6% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 272.6%, 155.47%, and 194.65% for Q4 2025, Q3 2025, and Q2 2025 respectively.